FUSION LEADERSHIP

John Valliant, PhD

Chief Executive Officer

Dr. Valliant is Founder and Chief Executive Officer of Fusion Pharmaceuticals. Dr. Valliant has been instrumental in securing both investment and scientific and medical collaborations with the industrial and academic partners of Fusion.

Prior to Fusion, Dr. Valliant founded the Centre for Probe Development and Commercialization (CPDC), a radiopharmaceutical research and development centre of excellence established in 2008 through funding from the Federal and Provincial governments, industry and academic partners. The CPDC is focused on discovering, developing and distributing the next generation of molecular imaging probes. The CPDC also plays an important role in Canada’s health care system, manufacturing and delivering a reliable, daily supply of imaging probes to hospitals and clinics nationally and internationally.
Dr. Valliant is also a Professor in the Department of Chemistry and Chemical Biology at McMaster University.

In 2009, Dr. Valliant was selected as one of Canada’s Top 40, Under 40, a distinction that recognizes his work at CPDC and McMaster University to advance molecular imaging probe technologies, improve patient care and spur economic growth through the commercialization of Canadian technologies. In 2015, he received the Brockhouse Canada Prize for Interdisciplinary Research in Science and Engineering from NSERC, recognizing his contribution to a team of researchers from physics, chemistry and nuclear medicine, who developed a breakthrough technology that uses hospital-based cyclotrons to produce critical medical isotopes.

Dr. Valliant completed his PhD at McMaster University, and followed with a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT).

Eric Burak, PhD

Chief Scientific Officer

Dr. Burak has more than 20 years of pharmaceutical research and development experience in both biotechnology and large pharmaceutical companies. Before joining Fusion, he was Vice President of Development at Theracos Inc., where he was responsible for all research, clinical development and manufacturing activities for a company developing drugs to treat Type 2 diabetes. Previous positions include Vice President of Preclinical and Early Clinical Development at Rib-X Pharmaceuticals, Inc., a venture-funded antibiotic company, and Director of Drug Metabolism and Pharmacokinetics at Guilford Pharmaceuticals, Inc.

Dr. Burak’s experience has focused on integrating discovery and development processes to accelerate the identification and development of new therapeutic agents. He has submitted 14 Investigational New Drug Applications (INDs) and has developed two approved products across multiple therapeutic areas including oncology, cardiovascular, antibiotics, diseases of the central and peripheral nervous system, anesthesia/sedation, diabetes, and wound healing.

Dr. Burak holds a PhD in Analytical Chemistry from Temple University and a BSc in Chemistry from Drexel University.

John Crowley, CPA

Chief Financial Officer

Mr. Crowley brings over 20 years of global finance and operational experience in the life sciences industry to Fusion. He most recently served as Executive Vice President and Chief Financial Officer of Merus, Inc., a publicly traded oncology company, where he led the execution of financial strategy and operations as well as investor relations activities. Prior to Merus, Mr. Crowley served as the Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer of Charles River Laboratories, Inc. where he implemented a finance transformation initiative to restructure the finance operating model in support of an aggressive acquisition strategy. Previously, Mr. Crowley held senior corporate finance positions at Ironwood Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., and Sunovion Pharmaceuticals, Inc., where he supported several commercial launches, financings, and business development transactions in rapidly growing companies. Mr. Crowley is a Certified Public Accountant and graduated Summa Cum Laude from Babson College with BS degrees in both Economics and Accountancy.

James O'Leary, MD

Chief Medical Officer

Dr. O'Leary brings to Fusion more than 20 years of oncology industry experience including roles within biotechnology companies such as ImmunoGen, Idera Pharmaceuticals, Array Biopharma, and Deciphera, and pharmaceutical companies including Takeda, Bayer and Pfizer. During his time at Takeda, Dr. O'Leary was a global project team leader for a late stage asset directing global strategy and regulatory approvals. At ImmunoGen, he was the CMO and was responsible for guiding the strategic direction and execution of all clinical programs, including antibody-drug conjugates. Prior to joining the biopharmaceutical industry, Dr. O'Leary was a medical reviewer with the U.S. Food and Drug Administration. Before that, he was a practicing oncologist in New York. Dr. O'Leary obtained his doctor of medicine degree from the State University of New York, Health Science Center at Brooklyn and completed a fellowship in oncology/hematology at New York University Medical Center.

Marc Schwabish, PhD

Senior Vice President, Business Development and US Operations

Marc Schwabish has a diverse background spanning Biopharma, Finance, Consulting, and Science. He was previously Head of US Pharma Business Development and Licensing at Bayer. He worked across Bayer’s therapeutic areas, focusing on late stage development opportunities, commercialized assets, and innovative partnerships. Prior to Bayer, Dr. Schwabish had both business development and alliance management responsibilities at Eisai. His deal experience at Eisai covered a range of diseases and stages of assets, from early research technologies through commercialized therapeutics. Dr. Schwabish previously worked in Healthcare Investment Banking at RBS (Leverage Finance and M&A), Pharma Strategy Consulting at Leerink Swann (now Guidehouse), and in research and development and product management at other pharmaceutical and biotechnology companies. He has closed over 25 transactions across anti-infectives, cardiology, gastrointestinal, metabolism, neurology, oncology, thrombosis, and women’s healthcare.

Dr. Schwabish holds a PhD in Biochemistry and Molecular Pharmacology from Harvard and a BS in Biology from Cornell.